logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Ventus Therapeutics U.s., Inc.

USPTO Granted Patents = 13


Trademarks = 4

Forward Citations = 30

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Stéphane Dorich (12 out of 14 patents)

silverMedal Stéphane Ciblat (4 out of 5 patents)

bronzeMedal Amandine Chefson (3 out of 3 patents)

4.  Miguel St-onge (2 out of 2 patents)

5.  Alexandre Côté (2 out of 2 patents)

6.  Ramsay Beveridge (1 out of 1 patent)

7.  Luke J Murphy (1 out of 1 patent)

8.  Jason Burch (1 out of 1 patent)

9.  Miguel St-Onge (3 patents)

10.  Jason Burch (0 patent)

11.  Ramsay Beveridge (0 patent)


13 patents:

1. 12516060 - Solid freebase forms of 5-chloro-2-(4-((2-hydroxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-yl)phenol for inhibiting NLRP3 and uses thereof (2026-01-06),
2. 12441728 - Pyridazine compounds for inhibiting NLRP3 (2025-10-14),
3. 12410167 - Pyridazine compounds for inhibiting NLRP3 (2025-09-09),
4. 12398136 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-08-26),
5. 12351578 - Compounds for inhibiting NLRP3 and uses thereof (2025-07-08),
6. 12331048 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-06-17),
7. 12312351 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-05-27),
8. 12312350 - Compounds for inhibiting NLRP3 and uses thereof (2025-05-27),
9. 12281112 - Compounds for inhibiting NLRP3 and uses thereof (2025-04-21),
10. 12195460 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors (2025-01-14),
11. 12168657 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives (2024-12-17),
12. 11618751 - Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives (2023-04-04),
13. 11319319 - Compounds for inhibiting NLRP3 and uses thereof (2022-05-03),
Company Overview
Ventus Therapeutics, based in Waltham, MA, specializes in the development of innovative therapeutics targeting protein misfolding and aggregation diseases. The company leverages advanced computational and structural biology techniques to design small molecules that modulate protein interactions, aiming to address unmet medical needs in various therapeutic areas. With a focus on precision medicine, Ventus is committed to transforming the treatment landscape for patients suffering from complex diseases.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

13 Patents

#108 in Waltham, MA

#1,443 in Massachusetts

#23,854 in US

#45,081 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Ventus Therapeutics U.s., Inc.

Forward Citations = 30

11 inventors:

goldMedal Stéphane Dorich (12 out of 14 patents)

silverMedal Stéphane Ciblat (4 out of 5 patents)

bronzeMedal Amandine Chefson (3 out of 3 patents)

4.  Miguel St-onge (2 out of 2 patents)

5.  Alexandre Côté (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ventus Therapeutics U.s., Inc.. Retrieved from https://idiyas.com/company/ventus-therapeutics-u-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…